2,766 Shares in Repligen Co. (NASDAQ:RGEN) Acquired by IHT Wealth Management LLC

IHT Wealth Management LLC purchased a new stake in Repligen Co. (NASDAQ:RGEN) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 2,766 shares of the biotechnology company’s stock, valued at approximately $407,000.

Several other hedge funds have also added to or reduced their stakes in the business. First Turn Management LLC bought a new position in shares of Repligen in the third quarter valued at about $13,202,000. Geneva Capital Management LLC raised its holdings in Repligen by 8.5% in the 3rd quarter. Geneva Capital Management LLC now owns 138,677 shares of the biotechnology company’s stock valued at $20,638,000 after acquiring an additional 10,908 shares during the period. Banque Pictet & Cie SA lifted its position in Repligen by 74.6% during the second quarter. Banque Pictet & Cie SA now owns 34,515 shares of the biotechnology company’s stock worth $4,351,000 after acquiring an additional 14,746 shares during the last quarter. Diversified Trust Co boosted its holdings in shares of Repligen by 3.7% during the second quarter. Diversified Trust Co now owns 2,949 shares of the biotechnology company’s stock worth $372,000 after acquiring an additional 106 shares during the period. Finally, Thrivent Financial for Lutherans grew its position in shares of Repligen by 240.5% in the second quarter. Thrivent Financial for Lutherans now owns 601,829 shares of the biotechnology company’s stock valued at $75,866,000 after purchasing an additional 425,061 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

RGEN has been the subject of several recent research reports. Royal Bank of Canada restated an “outperform” rating and issued a $205.00 price target on shares of Repligen in a research note on Thursday, September 26th. StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a research report on Friday, November 22nd. Wolfe Research began coverage on shares of Repligen in a research report on Thursday, November 14th. They set a “peer perform” rating on the stock. Finally, Wells Fargo & Company initiated coverage on shares of Repligen in a report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price objective for the company. Four research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $190.25.

Insider Buying and Selling

In related news, Director Anthony Hunt sold 22,191 shares of the company’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the transaction, the director now directly owns 139,840 shares in the company, valued at $20,328,540.80. This represents a 13.70 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 1.20% of the stock is owned by corporate insiders.

Repligen Price Performance

Shares of NASDAQ:RGEN opened at $149.20 on Monday. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $8.36 billion, a PE ratio of -403.24, a PEG ratio of 4.48 and a beta of 0.96. The firm has a 50 day moving average of $141.45 and a 200-day moving average of $141.66. Repligen Co. has a 12 month low of $113.50 and a 12 month high of $211.13.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.34 by $0.09. The business had revenue of $154.87 million during the quarter, compared to the consensus estimate of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The company’s revenue was up 9.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.23 earnings per share. On average, equities research analysts predict that Repligen Co. will post 1.52 EPS for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.